Everest Medicines (HKSE:01952) FCF Yield % : -16.30 (As of May. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Everest Medicines's Trailing 12-Month Free Cash Flow is HK$-1,132.2 Mil, and Market Cap is HK$6,946.0 Mil. Therefore, Everest Medicines's FCF Yield % for today is -16.30%.

The historical rank and industry rank for Everest Medicines's FCF Yield % or its related term are showing as below:

HKSE:01952' s FCF Yield % Range Over the Past 10 Years
Min: -55.29 Med: -26.78 Max: -12.71
Current: -16.3

During the past 6 years, the highest FCF Yield % of Everest Medicines was -12.71%. The lowest was -55.29%. And the median was -26.78%.

HKSE:01952's FCF Yield % is ranked worse than
52.29% of 1551 companies
in the Biotechnology industry
Industry Median: -14.28 vs HKSE:01952: -16.30

Everest Medicines's FCF Margin % for the quarter that ended in Dec. 2023 was -387.17%.

Everest Medicines FCF Yield % Historical Data

The historical data trend for Everest Medicines's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines FCF Yield % Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-5.93

-21.24

-33.41

-16.96

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial					-30.74	-24.56	-37.38	-17.10	-14.85

Competitive Comparison of Everest Medicines's FCF Yield %

For the Biotechnology subindustry, Everest Medicines's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's FCF Yield % falls into.

Everest Medicines FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Everest Medicines's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1132.214	/	6674.5404
	=	-16.96%

Everest Medicines's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-495.628	*	2	/	6674.5404
	=	-14.85%

Everest Medicines FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Everest Medicines FCF Yield % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines